A detailed history of Morgan Stanley transactions in I Mab stock. As of the latest transaction made, Morgan Stanley holds 10,109 shares of IMAB stock, worth $16,882. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,109
Previous 516,696 98.04%
Holding current value
$16,882
Previous $981,000 98.17%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$1.54 - $2.37 $780,143 - $1.2 Million
-506,587 Reduced 98.04%
10,109 $18,000
Q4 2023

Feb 13, 2024

SELL
$1.21 - $1.9 $571,101 - $896,771
-471,985 Reduced 47.74%
516,696 $981,000
Q3 2023

Nov 15, 2023

BUY
$1.18 - $3.06 $642,499 - $1.67 Million
544,491 Added 122.58%
988,681 $1.31 Million
Q2 2023

Aug 14, 2023

SELL
$2.95 - $3.85 $1.98 Million - $2.58 Million
-670,982 Reduced 60.17%
444,190 $1.33 Million
Q1 2023

May 15, 2023

SELL
$3.08 - $7.39 $1.47 Million - $3.52 Million
-476,099 Reduced 29.92%
1,115,172 $3.86 Million
Q4 2022

Feb 14, 2023

SELL
$3.22 - $4.86 $970,936 - $1.47 Million
-301,533 Reduced 15.93%
1,591,271 $6.65 Million
Q3 2022

Nov 14, 2022

SELL
$4.01 - $12.34 $1.94 Million - $5.96 Million
-483,164 Reduced 20.34%
1,892,804 $7.59 Million
Q2 2022

Oct 27, 2022

BUY
$8.27 - $18.43 $6.22 Million - $13.9 Million
751,560 Added 46.27%
2,375,968 $26.8 Million
Q2 2022

Aug 15, 2022

BUY
$8.27 - $18.43 $6.22 Million - $13.9 Million
751,560 Added 46.27%
2,375,968 $26.8 Million
Q1 2022

Oct 27, 2022

SELL
$12.54 - $46.93 $9.42 Million - $35.3 Million
-751,560 Reduced 31.63%
1,624,408 $26.4 Million
Q1 2022

May 13, 2022

BUY
$12.54 - $46.93 $2.08 Million - $7.79 Million
166,052 Added 11.39%
1,624,408 $26.4 Million
Q4 2021

Feb 14, 2022

BUY
$45.28 - $74.5 $1.11 Million - $1.83 Million
24,544 Added 1.71%
1,458,356 $69.1 Million
Q3 2021

Nov 15, 2021

BUY
$57.18 - $84.43 $82 Million - $121 Million
1,433,812 New
1,433,812 $104 Million

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $139M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.